Summary
The global Zika Virus Infection Drug Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2019.
High incidence of Zika virus infection is expected to propel growth of the global Zika virus infection drugs market over the forecast period. For instance, in November 2019, The European Centers for Disease Control confirmed the first three cases of Zika that started in southern France. Moreover, availability of new drugs for the treatment of Zika virus infection is also expected to aid in growth of the market. For instance, in October 2019, researchers from Lewis Katz School of Medicine at Temple University, U.S. reported that rilpivirine, a drug used in the treatment of HIV, stops Zika virus by targeting enzymes that both HIV and Zika virus depend on for their replication.
R&D in Zika virus infection is expected to offer lucrative growth opportunities for players in the global Zika virus infection drugs market over the forecast period. For instance, in August 2020, researchers from Laboratório de Parasitologia, Instituto Butantan, São Paulo, Brazil, in an article published in PLOS Neglected Tropical Diseases, reported the genetic factors that reduce the placenta's capacity to protect the fetus from the Zika virus. Moreover, development of new strategies to combat Zika virus is also expected to aid in growth of the market. For instance, in June 2020, researchers from Switch Laboratory, Department of Cellular and Molecular Medicine, Belgium, reported deploying synthetic amyloids to trigger protein misfolding as a strategy to combat the influenza A and Zika virus.
However, under-diagnosis of Zika virus infection is expected to hinder growth of the global Zika virus infection drugs market over the forecast period. For instance, according to a new study, published in ‘PLOS Neglected Tropical Diseases’, in October 2020, over 100 million infections of Zika virus within Central and South America and the Caribbean went undetected between 2015 and 2018.
Key Takeaways
- High incidence of Zika virus infection is expected to propel growth of the global Zika virus infection drugs market over the forecast period
- Major players operating in the global Zika virus infection drugs market are focused on approval and launch of new products to expand their product portfolio. For instance, in August 2019, Moderna, Inc. received the U.S. Food and Drug Administration’s Fast Track designation for its investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults.
- Major players operating in the global Zika virus infection drugs market include, Emergent BioSolutions, Valneva, Moderna, Novavax, Johnson & Johnson, Themis Bioscience, Sanofi, IMV, Takeda Pharmaceutical, CaroGen, GeoVax, Tychan, and Inovio Pharmaceuticals
The Zika Virus Infection Drug Market report highlights product development and growth strategies such as merger and acquisition adopted by market players along with SWOT Analysis, PEST and Porter’s Five Forces analyses of the Zika Virus Infection Drug Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.
The Key Manufacturers covered in this Report:-
- Emergent BioSolutions
- Valneva
- Moderna
- Novavax
- Johnson & Johnson
- Themis Bioscience
- Sanofi
- IMV
- Takeda Pharmaceutical
- CaroGen
- GeoVax
- Tychan
- Inovio Pharmaceuticals
By the Product Type, the market is primarily segmented into:
By Applications, the market is segmented into:
- Hospital
- Homecare
- Clinic
- Other
The Report covers the following Regions:
- North America
- United States
- Canada
- Mexico
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Central & South America
- Middle East & Africa
- Turkey
- GCC Countries
- Egypt
- South Africa
Objective of the Zika Virus Infection Drug Market Report:
- To assess the size of the market by value and volume
- Analyze the Zika Virus Infection Drug Market in terms of regions and major countries
- Highlight recent developments and trends in the market
- Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
- Determine share of the Zika Virus Infection Drug Market in terms of various segments such as by product type, application, and end-user
- Offer accurate projection of the market for the forecast period using state-of –the-art tools and the current primary and secondary research approaches
- Discuss major factors that impact growth of the Zika Virus Infection Drug Market
The Zika Virus Infection Drug Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Zika Virus Infection Drug Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders:
- Material suppliers/wholesalers
- Market Distributors/traders
- Regulatory bodies
- Research organizations, and consulting firms
- Commercial research & developments (R&D)
- Trade associations and industry bodies
- Importers and exporters
- End-use industries
Available Customizations:
Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.
Request Discount 
Inquire Before Buy
